A 12-week Efficacy Evaluation of WBI-1001 Cream in Patients With Atopic Dermatitis: A Multi-centered, Double-blinded Study (6-week Placebo-controlled Phase Followed by a 6-week Non-placebo Controlled Phase).

NCT01098734 Phase 2 COMPLETED

Welichem Biotech has developed a small molecule drug candidate, WBI-1001, that selectively targets the pathogenic features of inflammatory skin diseases, including atopic dermatitis (a form of eczema).The purpose of this clinical trial is to further test the safety and efficacy of WBI-1001 as a topically applied cream over an extended period of 12 weeks on patients with mild to moderate atopic dermatitis.

Details

Lead sponsor	Welichem Biotech Inc.
Phase	Phase 2
Status	COMPLETED
Enrolment	148
Start date	2009-11
Completion	2010-11

Conditions

• Dermatitis, Atopic

Interventions

• WBI-1001

Primary outcomes

• Investigator's Global Assessment (IGA) score — The change from baseline to 6 weeks.
  To evaluate the efficacy of the 0.5% and 1.0% WBI-1001 creams in comparison with the vehicle placebo.

Countries

Canada